



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: August 14, 2009
To: Primary Clinical Research Associates
From: Linda S. Long
Research Protocol Specialist III
Re: **N064B, Randomized Phase II Trial of Panitumumab, Erlotinib, and Gemcitabine vs. Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma**

The Evaluation/Treatment Form for Arm B has been revised as follows:

Form Title	Brief Description of Edit
Evaluation/Treatment Form (Arm B)	Under the “dose limiting toxicity” section, ANC has been revised to read: ANC \geq Grade 3 for \geq7 days

If you have any questions, please feel free to contact me.

Enclosure